Principles of alemtuzumab immunoablation in hematopoietic cell transplantation for non-malignant diseases in children: A review

Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease

(2016) Santosh L. Saraf et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan–Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation

(2016) Khilna Patel et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation

(2016) Pooja Khandelwal et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Long-Term Follow-Up after Reduced-Intensity Conditioning and Stem Cell Transplantation for Childhood Nonmalignant Disorders

(2016) Lisa M. Madden et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A trial of unrelated donor marrow transplantation for children with severe sickle cell disease

(2016) Shalini Shenoy et al.   BLOOD

CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment

(2016) Ryuichi Hotta et al.   PLoS One

Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies

(2015) Allison A. King et al.   AMERICAN JOURNAL OF HEMATOLOGY

Outcomes of mismatched and unrelated donor hematopoietic stem cell transplantation in Fanconi anemia conditioned with chemotherapy only

(2015) M. M. Chao et al.   ANNALS OF HEMATOLOGY

Impact of Serotherapy on Immune Reconstitution and Survival Outcomes After Stem Cell Transplantations in Children: Thymoglobulin Versus Alemtuzumab

(2015) Laura Willemsen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin

(2015) Alok Kothari et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen

(2015) Rebecca A. Marsh et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT

(2015) R. A. Marsh et al.   BLOOD

Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT

(2015) C K Brierley et al.   BONE MARROW TRANSPLANTATION

Guidelines for the diagnosis and management of adult aplastic anaemia

(2015) Sally B. Killick et al.   BRITISH JOURNAL OF HAEMATOLOGY

Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working P

(2015) Carlo Dufour et al.   BRITISH JOURNAL OF HAEMATOLOGY

Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases

(2015) Daniela Rau et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Alemtuzumab based reduced intensity transplantation for pediatric severe aplastic anemia

(2015) Alexander Ngwube et al.   PEDIATRIC BLOOD & CANCER

Outcomes of Hematopoietic Cell Transplantation in Adult Patients with Acquired Aplastic Anemia Using Intermediate-Dose Alemtuzumab-Based Conditioning

(2014) Nada Hamad et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation

(2014) F Baron et al.   BONE MARROW TRANSPLANTATION

Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease

(2014) M Bhatia et al.   BONE MARROW TRANSPLANTATION

Nonmyeloablative HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Phenotype

(2014) Matthew M. Hsieh et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy

(2014) O. Tuohy et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Autoimmune thyroid disease following alemtuzumab therapy and hematopoietic cell transplantation in pediatric patients with sickle cell disease

(2014) Kristen M. Williams et al.   PEDIATRIC BLOOD & CANCER

Mixed chimerism and graft loss in pediatric recipients of an alemtuzumab-based reduced-intensity conditioning regimen for non-malignant disease

(2014) Benjamin R. Oshrine et al.   PEDIATRIC BLOOD & CANCER

A trial of alemtuzumab adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency

(2014) Christopher C. Dvorak et al.   PEDIATRIC TRANSPLANTATION

In vivoT-cell depletion using alemtuzumab in family and unrelated donor transplantation for pediatric non-malignant disease achieves engraftment with low incidence of graft vs. host disease

(2014) M. A. Saif et al.   PEDIATRIC TRANSPLANTATION

The Effects of CAMPATH-1H on Cell Viability Do Not Correlate to the CD52 Density on the Cell Surface

(2014) Fuiyee Lee et al.   PLoS One

Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemia

(2013) Michael J. Eckrich et al.   AMERICAN JOURNAL OF HEMATOLOGY

Phase I Study of Alemtuzumab for Therapy of Steroid-Refractory Chronic Graft-versus-Host Disease

(2013) Sarah Nikiforow et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

An Intermediate Alemtuzumab Schedule Reduces the Incidence of Mixed Chimerism Following Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis

(2013) Rebecca A. Marsh et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A Novel Reduced-Intensity Conditioning Regimen for Unrelated Umbilical Cord Blood Transplantation in Children with Nonmalignant Diseases

(2013) Suhag H. Parikh et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation

(2013) J C Marsh et al.   BONE MARROW TRANSPLANTATION

Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery

(2013) Frank Gärtner et al.   CYTOTHERAPY

Human Invariant NKT Cell Subsets Differentially Promote Differentiation, Antibody Production, and T Cell Stimulation by B Cells In Vitro

(2013) S. G. Zeng et al.   JOURNAL OF IMMUNOLOGY

Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-Host Disease without Delaying Immune Reconstitution

(2012) Jason Law et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Unrelated Donor Cord Blood Transplantation for Children with Severe Sickle Cell Disease: Results of One Cohort from the Phase II Study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)

(2012) Naynesh R. Kamani et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Conditioning with Purine Analogs Leads to Good Engraftment Rates of Immunodepleted Grafts for Aplastic Anemia

(2012) Nicolas Novitzky et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anaemia following failure with immunosuppressive therapy: a United Kingdom multicentre retrospective experience

(2012) Sujith Samarasinghe et al.   BRITISH JOURNAL OF HAEMATOLOGY

Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis

(2012) Lisa Costelloe et al.   Expert Review of Neurotherapeutics

Human Peripheral Blood Mononuclear Cells Exhibit Heterogeneous CD52 Expression Levels and Show Differential Sensitivity to Alemtuzumab Mediated Cytolysis

(2012) Sambasiva P. Rao et al.   PLoS One

Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria

(2011) M. E. D. Flowers et al.   BLOOD

Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience

(2011) M. A. Slatter et al.   BLOOD

Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia

(2011) J. C. Marsh et al.   BLOOD

Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease

(2011) C. H. Gutierrez-Aguirre et al.   HAEMATOLOGICA

Alemtuzumab for the prevention and treatment of graft-versus-host disease

(2011) Junya Kanda et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort

(2011) M. Cossburn et al.   NEUROLOGY

Impact of Donor-Recipient Major ABO Mismatch on Allogeneic Transplantation Outcome According to Stem Cell Source

(2010) Nicolas Blin et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation

(2010) R. A. Marsh et al.   BLOOD

Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective

(2010) N Schub et al.   BONE MARROW TRANSPLANTATION

Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion

(2010) Martin Schmidt-Hieber et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Chronic Graft-Versus-Host Disease (GVHD) in Children

(2010) Kristin Baird et al.   PEDIATRIC CLINICS OF NORTH AMERICA

Alemtuzumab as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease: Results of a Phase II Study

(2009) Carmen Martínez et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab

(2009) L. R. Ambrose et al.   BLOOD

Melanoma following treatment with alemtuzumab for multiple sclerosis

(2009) A. A. Pace et al.   EUROPEAN JOURNAL OF NEUROLOGY

Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group

(2009) Stephan Stilgenbauer et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: A Children's Oncology Group report

(2009) Anne L. Angiolillo et al.   PEDIATRIC BLOOD & CANCER

Impact of graft-versus-host disease on survival

(2008) Marcelo C. Pasquini   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Post-transplant lymphoproliferative disease following reduced intensity conditioning transplants incorporating alemtuzumab

(2008) S W Bokhari et al.   BONE MARROW TRANSPLANTATION

Reduced-intensity conditioning is effective and safe for transplantation of patients with Shwachman–Diamond syndrome

(2008) D Bhatla et al.   BONE MARROW TRANSPLANTATION

Effects on erythropoiesis of alemtuzumab-containing reduced intensity and standard conditioning regimens

(2008) Aleksandar Mijovic et al.   BRITISH JOURNAL OF HAEMATOLOGY

Alemtuzumab for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease

(2007) David Gómez-Almaguer et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION